EU backs AstraZeneca, Daiichi's ENHERTU

The illegal importation case may not stop there, AstraZeneca CEO Pascal Soriot warned. “It’s possible that a similar issue is raised around Enhertu,” Soriot told reporters Thursday.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...
Also Read: FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients The U.K. Treasury, under the direction of Rachel Reeves, is reportedly considering ...
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3 ...